Kai Zhou

Kai Zhou is currently the Associate Director at NeuExcell Therapeutics. Prior to this, they were the Senior Scientist on the In-vivo target validation team at AstraZeneca, where they served as project lead and conducted behavioral phenotyping of CRISPR Cas9 genetically modified animal models and in-vivo and ex-vivo validation of cutting-edge drug delivery systems. Kai also served as a Guest Associate Editor in Cellular Neuropathology at Frontiers, a Postdoctoral Researcher at Karolinska Institutet, where they worked on the development of dysfunctional microglial depletion, repopulation and replacement therapies, a Senior Scientist at Tobii Pro, a Marketing Manager at CHaSE Stockholm and an Assistant Researcher at Goteborg Uni. During their time at Goteborg, they conducted research on developing strategies to repair radiotherapy- and hypoxia/ischemia-induced brain injury in children and published four peer-reviewed scientific papers. Kai also worked as a Clinical Marketing and Communication at Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where they learned how to communicate and fill the knowledge gap between the industries and doctors.

Kai Zhou obtained a Bachelor's degree in Pharmacy from Henan University from 2007 to 2011. In 2015, they began their PhD in Microglia, Immunology, Pediatric neuroscience, and Brain tumors at Karolinska Institutet, which they completed in 2020. In 2019, they were an exchange student at Harvard Medical School, studying Immunotherapy on Cancer and AD. In addition, Kai Zhou has obtained several certifications, including a Seminar on The Secret Life of Mice from Karolinska Institutet in 2021, a Data Visualization with R Track from DataCamp in 2021, Entrepreneurship Foundations from LinkedIn in 2020, an Introduction to Data Science from LinkedIn in 2020, and a Python Quick Start from LinkedIn in 2020.